ReviewInternational journal of molecular medicine2026
MTA2: Decoding pathogenic mechanisms, clinical implications and therapeutic frontiers across disease landscapes (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis‑associated protein 2 (MTA2), a crucial member of the metastasis‑associated family of transcriptional regulators, serves as a core component of the Mi‑2/nucleosome remodeling and deacetylase complex. It contributes to diverse human diseases through epigenetic regulation and integration of multiple signaling pathways. This paper systematically reviews the molecular and structural properties of MTA2 and investigates its functional mechanisms in both oncological and non‑oncological contexts, focusing on breast cancer, gastric cancer and hepatocellular carcinoma, emphasizing its biological roles in cancer metastasis, drug resistance and tumor microenvironment remodeling. Building on existing research, the review highlights the clinical significance of MTA2 as a potential diagnostic marker and therapeutic target in cancer and discusses targeted intervention strategies aimed at the MTA2‑related regulatory network. Finally, the development of highly specific inhibitors targeting MTA2 and the establishment of rapid MTA2 detection techniques for real‑time intraoperative margin assessment will fully unlock the clinical potential of MTA2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.